Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China

Objective: This study aimed to compare the economic evaluation of recombinant human thrombopoietin+rituximab (rhTPO + RTX) vs. RTX as second-line treatment for adult patients with immunologic thrombocytopenic purpura in China. Methods: The Markov model was used in our research. The response rate and...

Full description

Saved in:
Bibliographic Details
Published in:Front Med (Lausanne)
Main Authors: Rui, Mingjun, Wang, Yingcheng, Fei, Zhengyang, Shang, Ye, Ma, Aixia, Li, Hongchao
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2021
Subjects:
Medicine
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8012846/
https://ncbi.nlm.nih.gov/pubmed/33816534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2021.657539
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items